Molecular Formula | C17H18N2 |
Molar Mass | 250.34 |
Density | 1.102±0.06 g/cm3(Predicted) |
Melting Point | 257-258℃ |
Boling Point | 415.3±38.0 °C(Predicted) |
Solubility | DMSO: soluble10mg/mL, clear |
Appearance | powder |
Color | white to beige |
pKa | 11.52±0.10(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vitro study | In L6 myotubes, ZLN005 increases the expression of the PGC-1α gene and downstream genes by activating AMP-activated protein kinases, increasing glucose uptake and fatty acid oxidation, without significant toxicity. In rat primary hepatocytes, ZLN005 did not have the same effect, indicating cell type specificity. In L6 myotubes, ZLN005 increased the expression of PGC-1α and downstream genes by activating AMP-activated protein kinase, increasing glucose uptake and fatty acid oxidation, without significant toxicity. In rat primary hepatocytes, ZLN005 did not have the same effect, indicating cell type specificity. |
In vivo study | ZLN005(15 mg/kg, P. O.) produced antihyperglycemic and antihyperlipidemic effects while increasing insulin sensitivity in db/db mice and no effect in lean mice. ZLN005(15 mg/kg, P. O.) produced antihyperglycemic and antihyperlipidemic effects while increasing insulin sensitivity in db/db mice and no effect in lean mice. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R36 - Irritating to the eyes |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.995 ml | 19.973 ml | 39.946 ml |
5 mM | 0.799 ml | 3.995 ml | 7.989 ml |
10 mM | 0.399 ml | 1.997 ml | 3.995 ml |
5 mM | 0.08 ml | 0.399 ml | 0.799 ml |